Intraperitoneal Catumaxomab Prolongs Survival in Patients With Malignant Ascites from Ovarian Cancer
Markus Heiss
REFERENCE: ABSTRACT 5001, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
MARKUS HEISS, Klinikum Cologne, Merheim
For patients with malignant ascites as a result of ovarian cancer, a novel intraperitoneal therapy adding the trifunctional
MARKUS HEISS, Klinikum Cologne, Merheim
For patients with malignant ascites as a result of ovarian cancer, a novel intraperitoneal therapy adding the trifunctional